APG-2449 in Patients With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rак płuca bez drobnych komórek z mutacją ALK lub ROS1, lub inne zaawansowane nowotwory (przełyk, jajniki, opłucna)
- •Wyniki badań krwi i szpiku kostnego w normie
- •Prawidłowa funkcja nerek i wątroby
- •Prawidłowe funkcjonowanie serca
- •Co najmniej jedna zmiana widoczna na obrazach
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Kobieta w wieku rozrodczym musi mieć ujemny test ciąży
- •Gotowość do stosowania antykoncepcji przez 30 dni po zakończeniu badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
Beijing Cancer Hospital
Beijing, China
Fujian Medical University Union Hospital
Fuzhou, China
Fujian Cancer Hospital
Fuzhou, China
Sun-Yat Sen University Cancer Center
Guangzhou, China
The First affiliated hospital, Sun Yat-sen University
Guangzhou, China
Henan Provincial Oncology Hospital
Zhengzhou, China
Union Hospital medical college Huazhong University of Science and Technology
Wuhan, China
Hunan Provincial Oncology Hospital
Changsha, China
Zhejiang Provincial Oncology Hospital
Hangzhou, China
Trial contact
Yifan Zhai, M.D., Ph.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.